JP2024509920A5 - - Google Patents
Info
- Publication number
- JP2024509920A5 JP2024509920A5 JP2023555245A JP2023555245A JP2024509920A5 JP 2024509920 A5 JP2024509920 A5 JP 2024509920A5 JP 2023555245 A JP2023555245 A JP 2023555245A JP 2023555245 A JP2023555245 A JP 2023555245A JP 2024509920 A5 JP2024509920 A5 JP 2024509920A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- cancer
- formulation according
- seq
- bispecific anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158552P | 2021-03-09 | 2021-03-09 | |
| US63/158,552 | 2021-03-09 | ||
| PCT/IB2022/052009 WO2022189942A1 (en) | 2021-03-09 | 2022-03-07 | Treatment of cancers lacking egfr-activating mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509920A JP2024509920A (ja) | 2024-03-05 |
| JP2024509920A5 true JP2024509920A5 (enExample) | 2025-03-13 |
Family
ID=80738936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555245A Pending JP2024509920A (ja) | 2021-03-09 | 2022-03-07 | Ｅｇｆｒ活性化変異を欠くがんの治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220298248A1 (enExample) |
| EP (1) | EP4304644A1 (enExample) |
| JP (1) | JP2024509920A (enExample) |
| KR (1) | KR20230156094A (enExample) |
| CN (1) | CN116997358A (enExample) |
| AU (1) | AU2022233518A1 (enExample) |
| BR (1) | BR112023018278A2 (enExample) |
| CA (1) | CA3212669A1 (enExample) |
| CL (2) | CL2023002663A1 (enExample) |
| IL (1) | IL305700A (enExample) |
| JO (1) | JOP20230211A1 (enExample) |
| MX (1) | MX2023010633A (enExample) |
| WO (1) | WO2022189942A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116194141A (zh) | 2020-08-25 | 2023-05-30 | 詹森生物科技公司 | 具有egfr突变的非小细胞肺癌的治疗 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| JP6520705B2 (ja) * | 2013-03-19 | 2019-05-29 | 凸版印刷株式会社 | Ｅｇｆｒ阻害剤感受性予測方法 |
| KR102771603B1 (ko) | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| BR112021016149A2 (pt) * | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
-
2022
- 2022-03-07 BR BR112023018278A patent/BR112023018278A2/pt unknown
- 2022-03-07 EP EP22710172.2A patent/EP4304644A1/en not_active Withdrawn
- 2022-03-07 JP JP2023555245A patent/JP2024509920A/ja active Pending
- 2022-03-07 MX MX2023010633A patent/MX2023010633A/es unknown
- 2022-03-07 CA CA3212669A patent/CA3212669A1/en active Pending
- 2022-03-07 AU AU2022233518A patent/AU2022233518A1/en not_active Abandoned
- 2022-03-07 KR KR1020237034184A patent/KR20230156094A/ko active Pending
- 2022-03-07 IL IL305700A patent/IL305700A/en unknown
- 2022-03-07 WO PCT/IB2022/052009 patent/WO2022189942A1/en not_active Ceased
- 2022-03-07 CN CN202280019912.6A patent/CN116997358A/zh active Pending
- 2022-03-07 US US17/687,984 patent/US20220298248A1/en active Pending
-
2023
- 2023-09-06 CL CL2023002663A patent/CL2023002663A1/es unknown
- 2023-09-07 JO JOJO/P/2023/0211A patent/JOP20230211A1/ar unknown
-
2024
- 2024-04-17 CL CL2024001201A patent/CL2024001201A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2024153659A5 (enExample) | ||
| JP2024161445A (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| CN103533961B (zh) | 以表皮生长因子受体为靶向的治疗癌症的组合方法 | |
| JP2022521610A5 (enExample) | ||
| JP2023513297A5 (enExample) | ||
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| JP2025501175A (ja) | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ | |
| JP7783182B2 (ja) | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 | |
| JP2023539589A5 (enExample) | ||
| JP2026021442A (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物 | |
| CN118401259A (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| JP2022533211A (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| JP2024509920A5 (enExample) | ||
| JP2022531980A5 (enExample) | ||
| TW202329936A (zh) | 抗體-藥物結合物與parp1選擇性抑制劑之組合 | |
| TW202535477A (zh) | 抗ｂ７ｈ３抗體—藥物偶聯物治療癌症的方法 | |
| US20220298248A1 (en) | Treatment of Cancers Lacking EGFR- Activating Mutations | |
| Van Cutsem | Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer | |
| WO2025162287A1 (zh) | 抗her2抗体药物偶联物治疗肠癌的用途 | |
| WO2025087386A1 (zh) | 抗her2抗体药物偶联物治疗乳腺癌的用途 | |
| HK40102929A (zh) | 对缺失egfr激活突变的癌症的治疗 | |
| CN116265030A (zh) | 包含酪氨酸激酶抑制剂德立替尼的药物组合 | |
| WO2025131036A1 (zh) | 靶向her2的adc治疗乳腺癌的用途 |